先聲藥業 (2096.HK)

5.680 -0.020 (-0.35%) 收市：04:08PM HKT

先聲藥業

No. 699-18, Xuanwu Road
Xuanwu District
Nanjing 210042
China
86 25 8556 6666
https://www.simcere.com

版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 7,027

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Jinsheng Ren	Co-Founder, Chairman & CEO	8.02M	無	1962
Mr. Yushan Wan	CFO, Joint Company Secretary & Executive Director	7.55M	無	1970
Mr. Renhong Tang Ph.D.	Executive Director	9.85M	無	1981
Ms. Xi Wang	VP & Executive Director	1.91M	無	1983
Mr. Gaobo Zhou	Chief Investment Officer	無	無	1979
Mr. Quanfu Feng	Vice President of Marketing	無	無	1965
Mr. Tong Zhu	Chief Operating Officer of Simcere Zaiming	無	無	1978
Dr. Tamas Oravecz Ph.D.	Senior VP & Chief Scientific Officer of U.S.	無	無	無
Dr. Aik Han Goh	Senior VP & Chief Medical Officer	無	無	1975
Mr. Wang John	Senior Vice President	無	無	1961

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 HKD。

描述

Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. The company focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; COSELA, a trilaciclib hydrochloride for injection; Iremod, an iguratimod tablet; and XIANNUOXIN, a simnotrelvir tablets/ritonavir tablets. The company also offers promotion services for pharmaceutical products. It has a strategic regional licensing partnership with Vivoryon Therapeutics N.V. to develop and commercialize SIM0801 and other drugs in the Greater China region. In addition, the company engages in the manufacture of pharmaceutical ingredients; and property management business. Simcere Pharmaceutical Group Limited was founded in 1995 and is headquartered in Nanjing, China.

公司管治

截至 無 止，先聲藥業 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。